Last reviewed · How we verify

NCT05846035

Paraneoplastic Syndrome in Hepatocellular Carcinoma Patients

Status unknown Last updated 6 May 2023
What this trial tests

trial testing Triphasic C.T abdomen and pelvis in Hepatocellular Carcinoma Patients in 80 participants. Status unknown.

Timeline
15 April 2023
Primary endpoint
30 April 2024
30 April 2024

Quick facts

Lead sponsorSohag University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment80
Start date15 April 2023
Primary completion30 April 2024
Estimated completion30 April 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

Adults 40 to 100, any sex, with Hepatocellular Carcinoma Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world with rising incidence. Globally, there has been substantial variation in prevalence of risk factors for HCC over years, like control of viral hepatitis in developing countries but growing epidemic of fatty liver disease in developed world. Changing epidemiology of HCC is related to trends in these risk factors, Paraneoplastic syndromes (PNS) are defined as systemic, metabolic, or other distant consequences of malignancy resulting, either directly or indirectly, from production by the neoplasm of substances that gain access to the blood stream, thereby exerting their effects on distant organs or tissues There is four major HCC-associated paraneoplastic syndromes among Cirrhotic patients,i.e.hypercholesterolemia,hypoglycemia,hypercalcemia,and erythrocytosis .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05846035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing